Last year, Zhejiang Xinfu Pharmaceutical filed a lawsuit requesting that Shandong Xinfa Pharmaceutical Co., Ltd. and other infringements on its patents for invention of D-pantothenic acid calcium production process should be investigated for legal liability. Whether the lawsuit wins or loses, the impact on calcium pantothenate is difficult to make a conclusion.
On the evening of April 7, Zhejiang Xinfu Pharmaceutical Co., Ltd. issued an announcement to clarify the rumors of "Rat Rat". Since then, the company's stock has opened daily limit for two consecutive days.
In 2007, Xinfu Pharmaceutical, which created the myth of the first bullion in the small and medium plates, only had a stock price of more than ten yuan in early 2007, and reached 130 yuan by the end of the year. By 2008, the stock price plummeted. As of the end of the suspension, the stock price was only 16.88 yuan (recapitalization price was 46.73 yuan), and the decline was far greater than the broader market. These ups and downs of stock prices are all derived from a vitamin raw material called calcium D-pantothenate.
Right now, Xinfu Pharmaceutical and Shandong Xinfa are playing a patent dispute over calcium pantothenate. It is reported that in May, the trial of Xinfu Pharmaceutical's D-pantothenic acid calcium production process will be effective.
So how did calcium pantothenate trigger this lawsuit? What is the current price of calcium pantothenate? What is the effect of this lawsuit on calcium pantothenate?
“Big Cake†Encountered Encroaching In 2007, D-Panthenium Acetate led the wave of price increases for Chinese raw material medicines. In mid-2006, Xinfu Pharmaceutical announced that it would raise the calcium pantothenate price by about 15%. At that time, the price of calcium D-pantothenate was around RMB 60/kg. By the middle of 2007, this figure has reached the peak of 170-180 yuan / kg, a slight drop at the end of the year, recently maintained at about 120 to 130 yuan / kg.
According to statistics, domestic exports of calcium D-pantothenate and its panthenol in 2007 reached 6,800 tons, and the export value was nearly 100 million US dollars. The export volume increased by approximately 50% compared with the same period of last year, and both the quantity and the amount increased sharply.
As the largest D-pantothenate calcium production enterprise in China, Xinfu Pharmaceutical has naturally benefited greatly. The company's D-pantothenate products account for nearly 40% of the global market share. The company's annual report shows that in 2007 Xinfu Pharmaceutical's operating income, sales of calcium D-pantothenate accounted for more than 90% of the company's business income, due to the increase in calcium pantothenate rate of increase of up to 142.05%, operating profit Compared with the previous year, it increased by 33.01%, and the growth rate far exceeded that of other biochemical products.
In addition, there are three companies in Japan, namely Daiichi Pharmaceutical, BASF, and DSM, which produce calcium D-pantothenate. BASF and DSM are all produced by chemical synthesis, and they are also customers of Xinfu Pharmaceutical. Even though Japan's No. 1 Pharma is also produced by fermentation, the inherent cost advantages of China make Xinfu still slightly superior in terms of cost. Therefore, Xinfu Pharmaceutical has quite a say in the calcium pantothenate market.
In the previous round of market reshuffle, many manufacturers withdrew from the calcium pantothenate market at a low price, and switched to other varieties. There are only three or two left in the country, except Xinfu, which has a large output and Shandong Xinfa. Shandong Xinfa also produced calcium D-pantothenate by fermentation, and competed with Xinfu at a price slightly lower than Xinfu. The competition between the two sides has become increasingly fierce. Shandong Xinfa has expanded its output and market very quickly.
According to Shandong Xinfa's deputy general manager, Gai Naiming, the current production capacity of Shandong Xinfa is 5,000 tons/year. As of the end of 2007, Shandong Xinfa’s share in the domestic market was 60%. As early as the end of 2005, when Xinfu Pharmaceutical took over from Huzhou Lion King and Zibo Youfu to become calcium pantothenate, the annual output of Shandong Xinfa was only a few hundred tons, which was far from a threat.
On December 3, 2007, Xinfu Pharmaceutical filed a lawsuit with Hangzhou Intermediate People's Court in Zhejiang Province and asked Shandong Xinfa to infringe its invention patent for D-pantothenic acid production process, “producing D-pantolactone hydrolase. The legal responsibility of microorganisms and their methods for the preparation of D-pantoic acid. In early February 2008, the Zhejiang Provincial Intermediate People's Court issued a civil ruling, adjudicating Xinfu Pharmaceutical. Shandong Xinfa appealed to the Higher People's Court of Zhejiang Province within the statutory date. On the morning of March 28, 2008, the Higher People’s Court of Zhejiang Province held a hearing on the “jurisdiction dispute case†but did not make any ruling.
The impact of the patent case on the outcome of the second instance arbitration is still unknown. Will this result in a huge impact on the calcium pantothenate market?
Some analysts believe that if Shandong Xinfa wins the case, then the rapid expansion of Shandong Xinfa, low-cost strategy will lead to a sharp dive in the market price of calcium diphosphate, and Xinfu Shengtuo will further strengthen the concentration of D-pantothenic acid market. The price may increase further.
Wu Huifang, chief researcher at HealthNet, dismissed these views. She believes that the patent infringement case between Xinfu Pharmaceutical and Shandong Xinfa won no turmoil in the calcium pantothenate market, regardless of who wins or loses. The reason is that the change of supply and demand in market economy conditions is the dominant factor in determining market prices. Although the price increase in 2007 began with Xinfu Pharmaceutical's active price increase, the price increase in the latter part of the year was mainly caused by a combination of factors such as the imbalance between supply and demand causing market gaps and rising costs. At present, the profit of calcium pantothenate is still considerable, and the chemical synthesis method using higher costs is also profitable. In fact, there are indeed companies on the market that have chemically synthesized D-pantothenate to resume production. Therefore, even if Shandong Xinfa is infringed and ceases to use the fermentation method, it is not difficult to use synthetic methods for production.
Zhejiang Xinfu has formed the industrial chain of “Yuf's raw materials—the intermediates of the lion’s kings—Xinfu’s final products†and its scale advantage is still in place. According to the customs statistics of February 2008, Zhejiang Xinfu’s self-supported exports accounted for 56.58% of total domestic exports, Shandong Xinfa’s self-supported exports accounted for 28.67%, plus the share of exports through trading organizations, Xin Rich Pharmaceutical still accounts for 67.0 percent of exports, and it is still the dominant position. Although Shandong Xinfa's capacity expansion is relatively rapid, it is still hard to see in the short term.
In addition, the demand for calcium D-pantothenate in China is not large, and the price support mainly depends on the demand of foreign markets. Most of the orders for foreign trade contracts lasted for months or longer, and the prices were relatively stable. When the domestic highest price was more than 170 yuan/kg in 2007, the monthly export data showed that the average price was only around US$15/kg. After July, the price per kg did not fall below US$16.
Price remains weak and stable At present, the sales price of calcium D-pantothenate products is still at a relatively stable high level. Affected by many factors, there is great uncertainty in the future price trend.
It is understood that in recent days, Xin Fu Pharmaceutical's domestic price of calcium D-pantothenate is basically around 125 yuan / kg, Shandong Xinfa's product price is slightly lower, China Feed Industry Information Network data show that this price level has been maintained for some time, The current market can be relatively stable.
It is reported that the chemical production line of calcium D-pantothenate in Shanghai Xuxing Pharmaceutical Factory has already resumed production and has already been launched. The price is slightly lower than Xinfu and slightly higher than the new launch. It is reported that its annual output is 1,500 tons and it has not yet had a significant impact on the market.
Industry analysts expect global demand for calcium D-pantothenate to be around 21,000 tons in 2008. The customs statistics show that: According to self-reported production capacity, the current domestic production capacity has reached 13,000 tons. At present, the D-pantothenate calcium production capacities of several other manufacturers in the world are: DSM of the Netherlands, 4,000 tons; BASF, Germany, 3,200 tons; Japan's first pharmaceutical, 2,800 tons. Theoretical supply is slightly greater than demand, coupled with the impact of market expansion and interference factors on the output brought about by the natural growth rate of the market, and the basic balance between supply and demand is estimated.
It is reported that although the current price remains stable, the market demand is not strong. The raw material manufacturers have shifted the pressure of rising raw materials and other costs to the downstream consumer manufacturers. “The current price of calcium pantothenate has put pressure on downstream customers,†said one dealer in Sichuan.
The development of calcium pantothenate market in the end can't make a conclusion. However, one thing is certain: The market is eternal. In which direction we go, we must wait and see.
On the evening of April 7, Zhejiang Xinfu Pharmaceutical Co., Ltd. issued an announcement to clarify the rumors of "Rat Rat". Since then, the company's stock has opened daily limit for two consecutive days.
In 2007, Xinfu Pharmaceutical, which created the myth of the first bullion in the small and medium plates, only had a stock price of more than ten yuan in early 2007, and reached 130 yuan by the end of the year. By 2008, the stock price plummeted. As of the end of the suspension, the stock price was only 16.88 yuan (recapitalization price was 46.73 yuan), and the decline was far greater than the broader market. These ups and downs of stock prices are all derived from a vitamin raw material called calcium D-pantothenate.
Right now, Xinfu Pharmaceutical and Shandong Xinfa are playing a patent dispute over calcium pantothenate. It is reported that in May, the trial of Xinfu Pharmaceutical's D-pantothenic acid calcium production process will be effective.
So how did calcium pantothenate trigger this lawsuit? What is the current price of calcium pantothenate? What is the effect of this lawsuit on calcium pantothenate?
“Big Cake†Encountered Encroaching In 2007, D-Panthenium Acetate led the wave of price increases for Chinese raw material medicines. In mid-2006, Xinfu Pharmaceutical announced that it would raise the calcium pantothenate price by about 15%. At that time, the price of calcium D-pantothenate was around RMB 60/kg. By the middle of 2007, this figure has reached the peak of 170-180 yuan / kg, a slight drop at the end of the year, recently maintained at about 120 to 130 yuan / kg.
According to statistics, domestic exports of calcium D-pantothenate and its panthenol in 2007 reached 6,800 tons, and the export value was nearly 100 million US dollars. The export volume increased by approximately 50% compared with the same period of last year, and both the quantity and the amount increased sharply.
As the largest D-pantothenate calcium production enterprise in China, Xinfu Pharmaceutical has naturally benefited greatly. The company's D-pantothenate products account for nearly 40% of the global market share. The company's annual report shows that in 2007 Xinfu Pharmaceutical's operating income, sales of calcium D-pantothenate accounted for more than 90% of the company's business income, due to the increase in calcium pantothenate rate of increase of up to 142.05%, operating profit Compared with the previous year, it increased by 33.01%, and the growth rate far exceeded that of other biochemical products.
In addition, there are three companies in Japan, namely Daiichi Pharmaceutical, BASF, and DSM, which produce calcium D-pantothenate. BASF and DSM are all produced by chemical synthesis, and they are also customers of Xinfu Pharmaceutical. Even though Japan's No. 1 Pharma is also produced by fermentation, the inherent cost advantages of China make Xinfu still slightly superior in terms of cost. Therefore, Xinfu Pharmaceutical has quite a say in the calcium pantothenate market.
In the previous round of market reshuffle, many manufacturers withdrew from the calcium pantothenate market at a low price, and switched to other varieties. There are only three or two left in the country, except Xinfu, which has a large output and Shandong Xinfa. Shandong Xinfa also produced calcium D-pantothenate by fermentation, and competed with Xinfu at a price slightly lower than Xinfu. The competition between the two sides has become increasingly fierce. Shandong Xinfa has expanded its output and market very quickly.
According to Shandong Xinfa's deputy general manager, Gai Naiming, the current production capacity of Shandong Xinfa is 5,000 tons/year. As of the end of 2007, Shandong Xinfa’s share in the domestic market was 60%. As early as the end of 2005, when Xinfu Pharmaceutical took over from Huzhou Lion King and Zibo Youfu to become calcium pantothenate, the annual output of Shandong Xinfa was only a few hundred tons, which was far from a threat.
On December 3, 2007, Xinfu Pharmaceutical filed a lawsuit with Hangzhou Intermediate People's Court in Zhejiang Province and asked Shandong Xinfa to infringe its invention patent for D-pantothenic acid production process, “producing D-pantolactone hydrolase. The legal responsibility of microorganisms and their methods for the preparation of D-pantoic acid. In early February 2008, the Zhejiang Provincial Intermediate People's Court issued a civil ruling, adjudicating Xinfu Pharmaceutical. Shandong Xinfa appealed to the Higher People's Court of Zhejiang Province within the statutory date. On the morning of March 28, 2008, the Higher People’s Court of Zhejiang Province held a hearing on the “jurisdiction dispute case†but did not make any ruling.
The impact of the patent case on the outcome of the second instance arbitration is still unknown. Will this result in a huge impact on the calcium pantothenate market?
Some analysts believe that if Shandong Xinfa wins the case, then the rapid expansion of Shandong Xinfa, low-cost strategy will lead to a sharp dive in the market price of calcium diphosphate, and Xinfu Shengtuo will further strengthen the concentration of D-pantothenic acid market. The price may increase further.
Wu Huifang, chief researcher at HealthNet, dismissed these views. She believes that the patent infringement case between Xinfu Pharmaceutical and Shandong Xinfa won no turmoil in the calcium pantothenate market, regardless of who wins or loses. The reason is that the change of supply and demand in market economy conditions is the dominant factor in determining market prices. Although the price increase in 2007 began with Xinfu Pharmaceutical's active price increase, the price increase in the latter part of the year was mainly caused by a combination of factors such as the imbalance between supply and demand causing market gaps and rising costs. At present, the profit of calcium pantothenate is still considerable, and the chemical synthesis method using higher costs is also profitable. In fact, there are indeed companies on the market that have chemically synthesized D-pantothenate to resume production. Therefore, even if Shandong Xinfa is infringed and ceases to use the fermentation method, it is not difficult to use synthetic methods for production.
Zhejiang Xinfu has formed the industrial chain of “Yuf's raw materials—the intermediates of the lion’s kings—Xinfu’s final products†and its scale advantage is still in place. According to the customs statistics of February 2008, Zhejiang Xinfu’s self-supported exports accounted for 56.58% of total domestic exports, Shandong Xinfa’s self-supported exports accounted for 28.67%, plus the share of exports through trading organizations, Xin Rich Pharmaceutical still accounts for 67.0 percent of exports, and it is still the dominant position. Although Shandong Xinfa's capacity expansion is relatively rapid, it is still hard to see in the short term.
In addition, the demand for calcium D-pantothenate in China is not large, and the price support mainly depends on the demand of foreign markets. Most of the orders for foreign trade contracts lasted for months or longer, and the prices were relatively stable. When the domestic highest price was more than 170 yuan/kg in 2007, the monthly export data showed that the average price was only around US$15/kg. After July, the price per kg did not fall below US$16.
Price remains weak and stable At present, the sales price of calcium D-pantothenate products is still at a relatively stable high level. Affected by many factors, there is great uncertainty in the future price trend.
It is understood that in recent days, Xin Fu Pharmaceutical's domestic price of calcium D-pantothenate is basically around 125 yuan / kg, Shandong Xinfa's product price is slightly lower, China Feed Industry Information Network data show that this price level has been maintained for some time, The current market can be relatively stable.
It is reported that the chemical production line of calcium D-pantothenate in Shanghai Xuxing Pharmaceutical Factory has already resumed production and has already been launched. The price is slightly lower than Xinfu and slightly higher than the new launch. It is reported that its annual output is 1,500 tons and it has not yet had a significant impact on the market.
Industry analysts expect global demand for calcium D-pantothenate to be around 21,000 tons in 2008. The customs statistics show that: According to self-reported production capacity, the current domestic production capacity has reached 13,000 tons. At present, the D-pantothenate calcium production capacities of several other manufacturers in the world are: DSM of the Netherlands, 4,000 tons; BASF, Germany, 3,200 tons; Japan's first pharmaceutical, 2,800 tons. Theoretical supply is slightly greater than demand, coupled with the impact of market expansion and interference factors on the output brought about by the natural growth rate of the market, and the basic balance between supply and demand is estimated.
It is reported that although the current price remains stable, the market demand is not strong. The raw material manufacturers have shifted the pressure of rising raw materials and other costs to the downstream consumer manufacturers. “The current price of calcium pantothenate has put pressure on downstream customers,†said one dealer in Sichuan.
The development of calcium pantothenate market in the end can't make a conclusion. However, one thing is certain: The market is eternal. In which direction we go, we must wait and see.
Automatic Winding Machine
Flying Man motor winding machine is widely applied in laminating, slitting and die cutting for shield materials, sticky materials, insulating materials, conductive materials, electronic materials, such as paper rolls, label rolls, film rolls, PVC rolls, Mylar rolls, foil rolls, foam rolls, copper foils. and etc.
Automatic Unwinding and Rewinding Machine for roll materials.
Winding Machine,Motor Winding Machine,Motor Rewinding Machine,Automatic Winding Machine
Suzhou Flying Man Assembly Automation Co., Ltd. , https://www.flyingmancuttingmachine.com